Amrutanjan Health Care: 132-Year-Old Balm Business Still Rubbing Profits In


1. At a Glance

Founded in 1893, Amrutanjan has been relieving India’s headaches for over a century — and shareholders’ headaches for most of that time too. From ayurvedic balm to women’s hygiene and even packaged juice (yes, really), the company is debt-free, dividend-paying, and steady… but with growth speed somewhere between “monsoon traffic” and “government file clearance.”


2. Introduction

Amrutanjan is basically the Reliance Jio of the 19th century — when it launched, it disrupted a pain balm market that barely existed. The brand has outlived colonial rule, multiple recessions, and more cricket captains than you can count.

Today, it plays in three categories:

  1. Pain Management: Ayurvedic balms, sprays.
  2. Women’s Hygiene: Sanitary products, hygiene kits.
  3. Beverages: Packaged fruit drinks.

That last one is like McDonald’s selling cement — diversification or distraction? Depends on your patience.


3. Business Model – WTF Do They Even Do?

Revenue streams:

  • Pain management products (~60% of sales).
  • Women’s hygiene (~20%).
  • Beverages (~20%).

Distribution:

  • Modern Trade leadership in Head Category (41.1% volume share in CY19).
  • Strong retail network across India.

Roast note: The balm business is cash-rich, but the beverage arm feels like the corporate equivalent of buying a treadmill and using it as a clothes hanger.


4. Financials Overview

FY25 Annual:

  • Revenue: ₹452 Cr (+7% YoY)
  • EBITDA: ₹58 Cr (~13% margin)
  • PAT: ₹51 Cr (+13% YoY)
  • EPS: ₹17.58
  • P/E: 35.4x
  • Debt: ~₹2 Cr (basically zero).

Q1 FY26:

  • Revenue: ₹94.05 Cr (+12.3% YoY)
  • PAT: ₹8.31 Cr (+79.9% YoY — low base effect).
  • EPS: ₹2.87.

P/E Recalc:
Q1 EPS ₹2.87 × 4 = ₹11.48 annualized → CMP ₹671 ÷ ₹11.48 ≈ 58.4x — suggesting FY26 consensus expects stronger H2.


5. Valuation (Fair Value RANGE)

Method 1 – P/E Approach

  • Sector mid-cap FMCG: 25–35x.
  • Applying 25–30x to FY25 EPS ₹17.58 → ₹439 – ₹527.

Method 2 – EV/EBITDA

  • FY25 EBITDA: ₹58 Cr.
  • Applying 15–18x → EV ₹870 – ₹1,044 Cr.
  • Add cash (₹51 Cr), subtract debt (₹2 Cr) → Equity Value: ₹919 – ₹1,095 Cr.
  • Per share (~2.88 Cr shares): ₹319 – ₹380.

Method 3 – DCF (Simplified)

  • FCF ~₹45 Cr, growth 8% for 5 years, terminal 3%, discount 11% → ₹420 – ₹460.
MethodFV LowFV

Leave a Reply

error: Content is protected !!